Brain-changes in women during pregnancy may be key in finding MS cure
The very thing that worried doctors about women with multiple sclerosis (MS) in pregnancy could be what leads them to a cure.
The very thing that worried doctors about women with multiple sclerosis (MS) in pregnancy could be what leads them to a cure.
Researcher-clinicians at The Alfred and Monash University conducted a study to understand the nature of decreased brain volume occurring in pregnant women with MS, out of concern that the changes are a sign of disease progression.
Instead, Professor Vilija Jokubaitis, who led the study, said the results were not only surprising, but "incredibly reassuring".
"Our study is the first to show that the brain volume changes doctors have worried about for many years after pregnancy are actually a normal physiological process," Professor Jokubaitis said, "It's not harming women at all."
In fact, Professor Jokubaitis said the reduction in brain volume is part of a process that prepares women for maternal caregiving.
"A woman's brain will restructure and change shape during pregnancy to allow her to bond with her child and respond to their needs," Professor Jokubaitis said.
The new findings represent a significant step forward in understanding MS and have already provided researchers with a new direction for research.
"We also know that MS often goes into remission during pregnancy," Prof Jokubaitis said.
"Taken together with what we've learned in this study, we're now trying to understand the biological mechanisms behind these changes, and whether they could reveal regenerative pathways that one day help us develop better treatments for MS."
Multiple sclerosis (MS) is an autoimmune condition where the body mistakenly attacks fatty material around the nerves, affecting the brain, spinal cord and optic nerves. It affects three times more women than men, and currently there is no cure.
"It is typically diagnosed between the ages of 20 and 40 years old, often before women have started or completed their families," Professor Jokubaitis said.
"That's why conversations about pregnancy are a crucially important part of care for women living with the disease."
Journal
Neurology Open Access
Method of Research
Observational study
Pregnancy-related brain volume changes in people with MS may be temporary
Highlights:
- In female participants with multiple sclerosis (MS), pregnancy was associated with a loss in total brain volume and volume of the outer layer of the brain.
- Brain volume loss was greatest in the first three months after childbirth with an average decrease in total brain volume of 0.86% and an average decrease in the volume of the outer layer of the brain of 1.39%.
- However, these volumes returned toward original levels within one to two years after childbirth.
- Researchers say brain volume reductions after pregnancy may reflect pregnancy-related changes rather than permanent MS-related damage to the brain.
- While the study found associations, it does not prove cause and effect.
MINNEAPOLIS — In those with multiple sclerosis (MS), pregnancy was associated with lower total brain volume and lower volume of the outer layer of the brain within the first three months after childbirth, according to a study published November 18, 2026, in Neurology® Open Access, an official journal of the American Academy of Neurology. However, the changes were temporary with most people regaining brain volume within one to two years.
Researchers also found that brain lesions, areas of damage or inflammation related to MS, remained stable during pregnancy and the first year after childbirth. They noted study participants were treated with modern MS medications called high-efficacy disease-modifying therapies.
While the study found an association between pregnancy and brain volume changes after childbirth, it does not prove cause and effect.
“Pregnancy is known to affect relapse rates in multiple sclerosis but less is known about how it may affect MS-related changes in the brain,” said study author Vilija G. Jokubaitis, PhD, of Monash University in Melbourne, Australia. “Our findings suggest that while decreases in brain volume can be seen in the few months immediately after childbirth, these changes may reflect pregnancy-related changes rather than permanent MS-related damage to the brain.”
The study involved 247 female participants with MS who had MS for an average of six years. Researchers compared 100 participants with 122 pregnancies to 147 participants who had never been pregnant.
All participants had multiple magnetic resonance imaging (MRI) brain scans. For those with MS, brain scans were taken as early as two years before pregnancy up to two years after childbirth.
Researchers reviewed brain scans to measure the volume of several brain areas, including the whole brain and the gray matter in the cerebral cortex, the outer layer of the brain. They also measured lesions, areas of tissue damage or inflammation in the brain caused by MS.
Researchers found the following changes:
- During the first three months after childbirth, brain volume loss was greatest, with an average decrease in total brain volume of 0.86% and an average decrease in the volume of the outer layer of the brain of 1.39%.
- On the first scan after childbirth, average annual decrease in total brain volume was 0.47% and average annual decrease in the volume of the outer layer of the brain was 0.74%. For people who were not pregnant, average annual total brain volume increased by 0.03% and average annual volume of the outer layer of the brain decreased by 0.07%.
Brain volume generally recovered over time, returning toward original levels within one to two years after childbirth. The average volume of brain lesions remained unchanged.
“These findings suggest that pregnancy-related brain volume changes may be influenced primarily by normal processes associated with pregnancy and childbirth, although MS disease activity may contribute in some cases,” said Jokubaitis. “Understanding this pattern may help clinicians interpret brain scans more accurately after childbirth.”
One limitation of the study was that brain scans were collected through routine clinical care at multiple centers using different scanners and imaging protocols. Another limitation was that brain scan timing varied among participants.
Discover more about MS at BrainHealth.com, a free public resource from the American Academy of Neurology. It offers a website, podcast, and books, connecting you with trusted information from the world’s leading experts in brain health. Follow BrainHealth.com on Facebook, X, and Instagram.
The American Academy of Neurology is the leading voice in brain health. As the world’s largest association of neurologists and neuroscience professionals with more than 44,000 members, the AAN provides access to the latest news, science and research affecting neurology for patients, caregivers, physicians and professionals alike. The AAN’s mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor who specializes in the diagnosis, care and treatment of brain, spinal cord and nervous system diseases such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine.
Explore the latest in neurological disease and brain health, from the minds at the AAN at AAN.com or find us on Facebook, X, Instagram, LinkedIn, and YouTube.
Journal
Neurology
Subject of Research
People
Article Title
Peripregnancy Inflammatory Lesion and Brain Volume Changes in Contemporary Women with Multiple Sclerosis
Article Publication Date
19-Nov-2026
COI Statement
McCombe has received speaker fees and travel grants from Novartis, Biogen, Teva, and Sanofi; K. Buzzard has received honoraria for presentations and/or educational support from Biogen, Sanofi-Genzyme, Merck, Roche, Alexion, and Teva, and she serves on medical advisory boards for Merck and Biogen; M. H. Barnett is honorary Chief Research Officer at SNAC, has served on scientific advisory boards for Biogen, Novartis and Genzyme, has received conference travel support from Biogen and Novartis, serves on steering committees for trials conducted by Novartis, and his institution has received research support from Biogen, Merck and Novartis; Y. Barnett is a consulting neuroradiologist for SNAC; M. Law reports no disclosures relevant to the manuscript; E. Lui reports no disclosures relevant to the manuscript; S. Jamadar is supported by an Australian Research Council Future Fellowship FT250100206; A. van der Walt has received travel support and served on advisory boards for Novartis, Biogen, Merck, and Roche, and she receives grant support from MS Australia and the NHMRC of Australia (GNT1196380); H. N. Beadnall has received honoraria for attendance at advisory boards and travel sponsorship from Biogen, Merck, Novartis, Roche, and Sanofi-Genzyme, speaking honoraria from Biogen, Merck, Novartis, Roche, and Sanofi-Genzyme, and she has been an investigator for clinical trials sponsored by Alexion, Biogen, Bristol Myers Squibb, Clene Nanomedicine, Merck, Novartis, Roche, and Sanofi-Genzyme; H. Butzkueven is an employee of Monash University and has accepted travel compensation from Merck, his institution receives honoraria for talks, steering committee activities, and research grants from Roche, Merck, Biogen, Novartis, and UCB Pharma, the Medical Research Future Fund (MRFF), the National Health and Medical Research Council (NHMRC) of Australia, Trish MS Foundation, MS Australia, and the Pennycook Foundation, and he receives personal compensation for steering group activities for the Brain Health Initiative from Oxford Health Policy Forum and is funded by an NHMRC Australia Investigator Grant (GNT1197339); V. G. Jokubaitis receives research grant support from the NHMRC of Australia (GNT2025360), F. Hoffmann-La Roche, MRFF, MS Australia, and the Pennycook Foundation, and she has received speaker honoraria from Novartis, Biogen, and MedEx Learning.
No comments:
Post a Comment